GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Renalytix RENX.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

5.45p

-0.91%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

$3.0m

FY2016FY2026

Net income

−$14.2m

FY2016FY2026

Free cash flow

−$11.0m

FY2016FY2026

Shareholders' equity

−$6.3m

FY2016FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2016
Revenue$3.0m$3.0m$2.3m$3.4m$3.0m$1.5m$780.6m—$64.45bn$55.48bn
Research and development—$900,000$9.4m$14.3m$14.6m$10.0m$61,118$530,118$1.08bn$1.03bn
Operating income−$14.0m−$17.2m−$29.6m−$42.4m−$53.2m−$31.9m−$138,101−$566,849$11.28bn$8.11bn
Net income−$14.2m−$20.4m−$33.5m−$45.6m−$45.3m−$34.7m−$131,795−$566,340$7.23bn$5.46bn
Diluted earnings per share-0.03-0.05-0.34-0.47-0.60-0.48-0.00-0.01262.891.91

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2016
Total assets$4.6m$6.1m$8.0m$30.6m$50.1m$102.6m$552,912$387,218—$59.39bn
Cash and short-term investments$1.4m$3.7m$5.4m$24.7m$41.3m$74.5m$191,119$123,106—$4.34bn
Total liabilities$11.0m$13.1m$15.8m$23.7m$19.5m$7.5m$71,440$10,108—$41.52bn
Debt$5.7m$8.3m$8.5m$12.2m$12.3m$352,000$8,328———
Shareholders' equity−$6.3m−$7.0m−$7.9m$7.0m$30.6m$71.5m$213,035$114,484—$24.91bn
Shares outstanding410m383m97m97m75m72m72m59m27m2,854m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2016
Cash from operations−$10.9m−$17.9m−$30.1m−$32.7m−$45.7m−$24.6m−$134,700−$82,419$7.88bn$7.05bn
Capital spending−$100,251−$6−$4,000−$694,000−$694,000−$1.6m−$17,566−$174,704−$1.51bn−$1.80bn
Free cash flow−$11.0m−$17.9m−$30.1m−$33.4m−$46.4m−$26.3m−$152,266−$257,123$6.37bn$5.24bn
Dividends paid———−$4.64bn−$5.10bn−$5.23bn−$63.2m−$62.4m−$3.92bn−$3.61bn

Latest quarters

By quarter end

Dec 2025Sept 2025Jun 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023
Revenue$800,000$800,000$1.7m$729,000$522,000$586,000$535,000$709,000
Operating income−$3.5m−$3.5m−$9.7m−$3.4m−$4.1m−$5.5m−$6.6m−$8.6m
Net income−$4.0m−$4.0m−$11.8m−$3.9m−$4.7m−$7.1m−$7.7m−$8.5m
Diluted earnings per share-0.01-0.01-0.03-0.04-0.05-0.07-0.08-0.09
Cash from operations−$2.0m−$2.0m—−$6.0m−$3.0m−$7.0m−$4.0m−$7.0m
Total assets$9.9m$9.9m—$11.4m$4.8m$8.0m$8.8m$11.3m
Cash and short-term investments$6.2m$6.2m—$9.6m$909,000$4.7m$4.7m$5.6m
Debt$4.9m$200,000—$8.2m$8.3m$8.5m$9.4m$8.5m
Shareholders' equity−$1.2m−$1.2m—−$1.4m−$11.3m−$7.9m−$11.1m−$8.0m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-4.0%15.1%-62.7%
Operating income-30.8%-15.2%—
Net income-32.2%-16.3%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-519.9%-882.1%-1165.2%—
Net margin-576.5%-971.8%-1198.6%—

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings-2.1-1.5-0.4-0.5-1.6-10.9-2259.5-314.7
Price to sales10.110.26.26.024.7255.00.4—

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.